Dr. Jean Hebert joined ARPA-H in August 2024 from the Albert Einstein College of Medicine where he served as a professor of genetics and neuroscience. Hebert is the founder of BE Therapeutics, a company focused on reversing age-related damage to brain tissue. His laboratory research focuses on stem cell transplantation, plasticity, neurodegeneration, and cortical health. In addition to his academic publications, Hebert is also the author of Replacing Aging, a book on regenerative medicine and the types of cellular damage accumulated in aging tissue.

Since childhood, Hebert has been interested in understanding how our bodies work and how to repair them. He has a doctorate in genetics from the University of California San Francisco and completed postdoctoral research at Stanford University studying the development of neurons that make up the neocortex. 

Danielle Capalino is an investor and innovator focused on early-stage commercialization at the intersection of health, technology, and innovation. She is the CEO of Neta: a pioneering new platform that bridges the gap between grant making and venture capital and makes it simple to deploy money into impactful businesses in a tax efficient way. By creating a new asset class called Grantvestments, Neta’s ultimate goal is to get technology out of the lab and into the world where it is needed. The genesis for Neta came from solving a problem Danielle faced running her own family foundation for the last decade. 

Prior to founding Neta, Danielle founded and managed an active investing group focused on early-stage companies emerging from universities fostering cross-border innovation in health and technology sectors.

Danielle brings deep academic credentials to her work, holding a BS in Brain and Cognitive Science from MIT and a Master's in Public Health Nutrition from Johns Hopkins University. Her commitment to advancing education and innovation is reflected in her advisory roles on the MIT Corporation Development Committee, the MIT Visiting Committee for Brain and Cognitive Sciences, and the Board of Advisors at the Tufts Friedman School of Nutrition Science and Policy.  

Michael Aberman, MD, MBA is currently a General Partner at Regeneron Ventures. Prior to joining Regeneron Ventures, Michael was the CEO and Co-founder of XenImmune Therapeutics, a seed stage biotech company. Previously, he was the president and chief executive officer of Quentis Therapeutics, an early-stage biotech company. Before Quentis, Michael spent over seven years at Regeneron, most recently as the Senior Vice President of Investor Relations and Strategy. In that role, he was a member of the senior management team and responsible for investor relations, corporate communications, business development, and corporate strategy. Michael joined Regeneron after six years as a biotechnology analyst at Credit Suisse and Morgan Stanley. Previously, he was Director of Business Development at Antigenics, Inc., an oncology-focused biotechnology company. Michael received his B.A. from Cornell University, his medical degree from the University of Toronto, completed residency training in internal medicine at New York Presbyterian Hospital, and received an M.B.A. from The Wharton School of Business.

Brent R. Stockwell, PhD, is the William R. Kenan Jr. Professor of Biological Sciences and Chair of the Department of Biological Sciences, and Professor of Chemistry in Arts & Sciences, and Professor of Pathology and Cell Biology, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center. His research involves the discovery of small molecules that can be used to understand and treat cancer and neurodegeneration, with a focus on biochemical mechanisms governing cell death. In a series of papers from 2003-2012, Dr. Stockwell discovered compounds that activate a previously unrecognized form of cell death that he termed ferroptosis. His lab defined key mechanisms governing ferroptosis, its therapeutic implications, and essential tools for studying this new form of cell death. There are now more than 24,000 papers on ferroptosis from hundreds of labs around the world. Dr. Stockwell has received numerous awards, including being elected to the US National Academy of Medicine, the 2024 Cell Death and Differentiation Award, and the Great Teacher of Columbia College Award. He has been in the top 1 percent of highly cited researchers the last five years and was ranked among the top 50 scientists in the world in 2025. He has published >200 scientific articles, been awarded 23 US patents, received >50 research grants for >$40 million, launched five startup companies and written a book for general audiences about drug discovery, The Quest for the Cure.